Emergent BioSolutions | EBS - Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
Acadia Pharmaceuticals USD 851.46M 31.77M 2026-03
Akebia Therapeutics USD 162.64M 22.2M 2026-03
ALKERMES USD 351.55M 37.02M 2026-03
Alnylam Pharmaceuticals USD 1.71B 53.53M 2026-03
Amarin USD 131.06M 3.6M 2026-03
ANI Pharmaceuticals USD 311.18M 25.59M 2026-03
BioMarin Pharmaceutical USD 2.22B 910.76M 2026-03
Coherus Biosciences USD 88.88M 14.47M 2025-12
Emergent BioSolutions USD 111.7M 23.9M 2023-12
Exelixis USD 226.15M 256.34M 2026-03
Glaxosmithkline GBP 3.3B 303M 2025-09
Heron Therapeutics USD 26.12M 2.53M 2026-03
Ionis Pharmaceuticals USD 1.92B 758M 2026-03
Ironwood Pharmaceuticals USD 220.47M 5.01M 2026-03
Lexicon Pharmaceuticals USD 38.09M 3.76M 2026-03
Lonza CHF 719M 188M 2025-12
Merck USD 5.33B 9.24B 2026-03
Moderna USD 1.91B 687M 2026-03
Myriad Genetics USD 124.4M 25.2M 2026-03
Nektar Therapeutics USD 15.12M 25.92M 2025-12
Neurocrine Biosciences USD 266.5M 446.5M 2026-03
Pacira USD 144.31M 14.24M 2026-03
Pfizer USD 1.7B 561M 2026-03
PTC Therapeutics USD 833.99M 150.66M 2026-03
Sanofi EUR 7.66B 1.25B 2025-12
Sarepta Therapeutics USD 464.45M 336.83M 2026-03
United Therapeutics USD 1.28B 277.4M 2026-03
Vanda Pharmaceuticals USD 84.85M 14.83M 2025-12
Xoma USD 143.9M 7.68M 2024-06